Orthocell (ASX:OCC) submitted a 510(k) application with the US Food and Drug Administration to sell its Remplir nerve repair device in the US market, according to a Thursday filing with the Australian bourse.
The submission is based on a regulatory study of Remplir, which met all the endpoints and provided key data to support the application, the filing said.
The 90-calendar day review process is expected to start between March and April 2025, with commercial distribution expected soon after, the filing said.
Shares fell nearly 5% in midday trade Thursday.
Price (AUD): $1.20, Change: $-0.06, Percent Change: -4.78%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.